These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8804007)

  • 41. Influence of the dialysis membrane on outcome of ESRD patients.
    Hakim RM
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S71-5. PubMed ID: 9892369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of high-flux hemodialysis on oxidant stress.
    Ward RA; Ouseph R; McLeish KR
    Kidney Int; 2003 Jan; 63(1):353-9. PubMed ID: 12472803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
    Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
    Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia.
    Shoji T; Hatsuda S; Tsuchikura S; Kimoto E; Kakiya R; Tahara H; Koyama H; Emoto M; Tabata T; Nishizawa Y
    Atherosclerosis; 2009 Dec; 207(2):579-84. PubMed ID: 19540497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of membrane flux and dialyzer biocompatibility on survival in end-stage diabetic nephropathy.
    Götz AK; Böger CA; Popal M; Banas B; Krämer BK
    Nephron Clin Pract; 2008; 109(3):c154-60. PubMed ID: 18663328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MicroRNA 499 gene expression in patients on hemodialysis with cardiovascular complications.
    El Sharkawy M; Aly O; Elsayed H; Ezzat H; Mohab A; Usama D
    Hemodial Int; 2017 Oct; 21 Suppl 2():S16-S21. PubMed ID: 29064177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In Vitro Dialysis of Cytokine-Rich Plasma With High and Medium Cut-Off Membranes Reduces Its Procalcific Activity.
    Willy K; Hulko M; Storr M; Speidel R; Gauss J; Schindler R; Zickler D
    Artif Organs; 2017 Sep; 41(9):803-809. PubMed ID: 28524237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipoprotein metabolism in chronic renal insufficiency.
    Saland JM; Ginsberg HN
    Pediatr Nephrol; 2007 Aug; 22(8):1095-112. PubMed ID: 17390152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR.
    García Moreira V; de la Cera Martínez T; Gago González E; Prieto García B; Alvarez Menéndez FV
    Clin Chem Lab Med; 2006; 44(12):1410-5. PubMed ID: 17163815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.
    Schröder M; Riedel E; Beck W; Deppisch RM; Pommer W
    Kidney Int Suppl; 2001 Feb; 78():S19-24. PubMed ID: 11168977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of subjective and hemodynamic tolerance of different high- and low-flux dialysis membranes in patients undergoing chronic intermittent hemodialysis: a randomized controlled trial.
    Bianchi G; Salvadé V; Lucchini B; Schätti-Stählin S; Salvadé I; Burnier M; Gabutti L
    Hemodial Int; 2014 Oct; 18(4):825-34. PubMed ID: 24865782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Lipoprotein (a) in children with end stage renal failure on maintenance hemodialysis and continuous ambulatory peritoneal dialysis].
    Zwolińska D; Szprynger K
    Przegl Lek; 1997; 54(5):320-3. PubMed ID: 9380806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study.
    Svensson M; Schmidt EB; Jørgensen KA; Christensen JH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2918-24. PubMed ID: 18436564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-flux versus low-flux haemodialysis membranes for end-stage kidney disease.
    Nephrology (Carlton); 2013 Apr; 18(4):313-4. PubMed ID: 23530531
    [No Abstract]   [Full Text] [Related]  

  • 55. [Clinical dialysis: new problems and new prospects].
    Locatelli F; Manzoni C; Pozzoni P; Pontoriero G; Di Filippo L
    G Ital Nefrol; 2004; 21(2):156-64. PubMed ID: 15351950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides].
    Wiemer J; Scherberich JE
    MMW Fortschr Med; 1999 Oct; 141(43):29-32. PubMed ID: 10912118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biocompatibility in haemodialysis: fact and fiction.
    Locatelli F; Manzoni C
    Curr Opin Nephrol Hypertens; 1997 Nov; 6(6):528-32. PubMed ID: 9375265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-flux versus low-flux membranes for end-stage kidney disease.
    Palmer SC; Rabindranath KS; Craig JC; Roderick PJ; Locatelli F; Strippoli GF
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD005016. PubMed ID: 22972082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.
    Macleod AM; Campbell M; Cody JD; Daly C; Donaldson C; Grant A; Khan I; Rabindranath KS; Vale L; Wallace S
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD003234. PubMed ID: 16034894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of dialysis membranes on lipoprotein profile of serum in haemodialysed patients.
    Kimak E; Solski J; Janicka L; Wojtysiak B; Zagojska M
    Int Urol Nephrol; 1998; 30(6):789-98. PubMed ID: 10195875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.